Brainstorm Cell Therapeutics Inc.
BCLI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $12,053 | $15,740 | $60,147 | $145,474 |
| - Cash | $187 | $1,300 | $772 | $18,856 |
| + Debt | $720 | $1,275 | $4,093 | $5,079 |
| Enterprise Value | $12,586 | $15,715 | $63,468 | $131,697 |
| Revenue | $849 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $849 | -$265 | -$285 | -$260 |
| % Margin | 100% | – | – | – |
| EBITDA | -$11,306 | -$16,927 | -$23,992 | -$24,279 |
| % Margin | -1,331.7% | – | – | – |
| Net Income | $11,623 | -$17,192 | -$24,277 | -$24,457 |
| % Margin | 1,369% | – | – | – |
| EPS Diluted | 2.19 | -4.48 | -9.93 | -10.09 |
| % Growth | 148.9% | 54.9% | 1.6% | – |
| Operating Cash Flow | -$9,093 | -$20,458 | -$19,320 | -$26,265 |
| Capital Expenditures | $0 | -$18 | -$29 | -$330 |
| Free Cash Flow | -$9,093 | -$20,476 | -$19,349 | -$26,595 |